Company
Our mission is to create real hopes
through innovative new drug developments
History
  • HOME
  • Company
  • History
2017~PRESENT Growth and Leap of Pinotbio
  • 2021
    06
    Signed a contract for the joint development of repebody-drug conjugate with ProEn Therapeutics Co., Ltd.

    Signed a contract for the joint development of aptamer-drug conjugate with Aptamer Sciences Co., Ltd.

    Signed a contract for the joint development of aptamer-drug conjugate with the UK’s Aptamer Group

    Signed a technology transfer contract with AkiraBio, USA, for NTX-301
    (for non-cancer drugs)

    Completed the phase 1 clinical trial of NTX-101
    05
    Acquired the approval of phase 1/2 clinical trial approval for NTX-301
    (ovarian cancer and bladder cancer) in Australia
    03
    Attracted a strategic investment (ST Pharm Co., Ltd.)
    02
    Started the administration of NTX-301 to clinical patients with blood cancer
  • 2020
    12
    Acquired the domestic phase 1 clinical trial approval for NTX-101
    11
    Signed a joint clinical development agreement for NTX-301 in Australia
    (Xennials Therapeutics)

    Attracted a venture capital investment (Series C, KRW 20 billion)
    07
    Established Pinotbio North America, Inc., the American branch
    04
    Changed its company name (Bionetics Co., Ltd. → Pinotbio Co., Ltd.)
    03
    Selected as an IPO organizer (NH Investment & Securities, KB Securities)
    02
    Acquired the phase 1/2 clinical trial approval for NTX-301 (blood cancer) in the US
  • 2019
    12
    Attracted a venture capital investment (Series B, KRW 10 billion)

    Completed the phase 1a clinical trial of NTX-301 (solid cancer) in the US
    06
    Completed the preclinical development of NTX-101
    04
    Completed the preclinical development of NTX-301 (blood cancer)
    01
    Started the phase 1a clinical trial of NTX-301 (solid cancer) in the US
  • 2018
    11
    Started the preclinical of NTX-301 (blood cancer)
    10
    Acquired the phase 1/2 clinical trial approval for NTX-301 (solid cancer) in the US (NCI CTEP Program in the US)

    Secured the exclusive license for NTX-301
    09
    Attracted a venture capital investment (Series A, KRW 10,89 billion)
    02
    Established and acquired corporate laboratory certification
  • 2017
    12
    Started the development of the PINOT-ADC™ platform
    11
    Attracted a venture capital investment (2nd seed round, KRW 3 billion)
    06
    Started the preclinical trial of NTX-301 (solid cancer)
    03
    Attracted a venture capital investment (1st seed round, KRW 800 million)

    Started the preclinical development of NTX-101
    02
    Established Bionetics Co., Ltd.